PSA Density Plus MRI May Improve Detection of Clinically Significant Prostate Cancer
Combining PSA density with prostate MRI findings improves the predictive performance of PI-RADS in men without a prior prostate cancer diagnosis.
PROSTATE CANCER ADVISOR
Prostate Cancer
Features
-
-
4Kscore May Help Predict Adverse Pathology at Radical Prostatectomy
In a study, a higher 4Kscore was significantly associated with a 16% greater risk of biochemical recurrence of prostate cancer following radical prostatectomy. -
SABR Found to Improve Outcomes in Recurrent Oligometastatic HSPC
In patients with recurrent oligometastatic hormone-sensitive prostate cancer, stereotactic ablative radiation therapy decreased the risk of disease progression compared with observation alone, a phase 2 study found. -
Genomic Alterations Linked to Outcomes in mCSPC
DNA sequencing in men with metastatic castration-sensitive prostate cancer revealed alterations in certain signaling pathways that predict worse overall survival and shorter progression time to castration-resistant disease. -
Prostate Cancer Immunotherapy Alone Is Not Enough
So far, prostate cancer immunotherapy has shown only modest benefits. To greatly improve outcomes, immunotherapy will need to be combined with other treatments, according to the authors of a recent review. -
Radiation Therapy After Prostate Surgery Worsens Sexual, Urinary Function
Allowing an approximately 24-month recovery period after prostate surgery before giving radiation therapy may be optimal for preserving erectile function provided oncologic control is not compromised, according to investigators. -
Fewer Systematic Biopsy Cores May Not Lower PCa Detection Rate
In a study of patients undergoing transperineal prostate biopsy, the detection rate of clinically significant prostate cancer did not differ significantly between targeted biopsy (TB) with fewer systematic biopsy (SB) cores and TB with SB of the whole prostate.
Latest Prostate Cancer News
Study May Clarify Which Systemic Drugs Offer Best Survival in mCSPC
A meta-analysis suggests that abiraterone or apalutamide added to androgen deprivation therapy for men with metastatic castration-sensitive prostate cancer offers the best overall survival.
Overall Cancer Death Rates Decreased From 1991 to 2018
Pace of annual decline in lung cancer mortality increased from 2009-2013 to 2014-2018 for men, women, overall
Higher Coffee Intake May Reduce Risk for Prostate Cancer
Pooled relative risk of 0.988 for each increment of one cup of coffee per day revealed in meta-analysis of cohort studies
Black Men Report More Regret Over Prostate Cancer Treatment Decisions
Mistrust and concerns about masculinity are important factors that influence Black men’s experience during prostate cancer management.
Use of Commercial Genomic Testing for Prostate Cancer ‘Highly Variable’ in the United States
Investigators evaluated a large sample of commercially insured patients with prostate cancer to assess use of tissue-based gene expression testing.
Overall Survival Data Added to Nubeqa Prescribing Information
Nubeqa, an androgen receptor inhibitor, was approved for the treatment of patients with nmCRPC based on data from the placebo-controlled phase 3 ARAMIS trial.
Advanced, Fatal Prostate Cancer Linked to Diet
Diets that promote hyperinsulinemia and inflammation increase the likelihood of advanced or fatal prostate cancer, a new study suggests.
Time to Say Goodbye to the DRE for Prostate Cancer Screening
With the advent of more reliable and accurate ways to screen for prostate cancer, such as PSA testing and prostate MRI, the authors argue that it is time to stop the “antiquated practice” of the digital rectal examination.
Mediterranean Diet May Lower Prostate Cancer Progression Risk
In a study of men on active surveillance for localized prostate cancer, each 1-unit increase in Mediterranean diet score, calculated based on patients’ baseline food frequency questionnaire information, was associated with a 12% decreased risk for Gleason grade group progression.
Orgovyx Now Available for Advanced Prostate Cancer
Orgovyx is an oral nonpeptide gonadotropin-releasing hormone (GnRH) receptor antagonist.
-
Loading...
-
Loading...
Want to read more?
Please login or register first to view this content.
Next post in Prostate Cancer
